Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Induction SBRT and Olaparib Followed by Combination Pembrolizumab/Olaparib in Gastric and Gastroesophageal Junction (GEJ) Cancers

NCT05379972 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT05379972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05379972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Induction SBRT and Olaparib Followed by Combination Pembrolizumab/Olaparib in Gastric and Gastroesophageal Junction (GEJ) Cancers
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
January 12, 2023
Completion date
January 22, 2026
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal cancer